文献速递免疫规划传染病防控与疫情报告

4月龄至6岁儿童含无细胞百日咳成分疫苗保护效果的匹配病例对照研究

[A matched case-control study on the effectiveness of acellular pertussis-containing vaccine among children aged 4 months to 6 years].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2026-01-01

该研究在江苏省哨点监测医院纳入2024年因咳嗽就诊并检测百日咳的4月龄至6岁儿童,采用1∶1个体匹配病例对照设计,共893对。结果显示aPV总体保护效果(VE)为74.87%(95%CI:60.46%~84.64%),且末剂接种后VE随时间推移呈衰减趋势。

要点

  • aPV对4月龄至6岁儿童百日咳总体VE为74.87%(95%CI:60.46%~84.64%)。
  • 接种1、2、3、4剂aPV的VE分别为45.88%、73.81%、78.62%、74.42%。
  • 完成4剂后随时间推移VE呈衰减趋势,间隔36~54月VE为70.61%。

核心结论

  • aPV预防儿童百日咳的总体VE较好,末剂接种后VE随时间推移呈衰减趋势。

研究设计与样本

  • 研究采用匹配病例对照设计,病例组为2024年江苏省百日咳哨点监测医院中百日咳核酸检测阳性的4月龄至6岁儿童。
  • 对照组按1∶1个体匹配选取,匹配因素包括现住址所在街道或乡镇相同或相邻、性别相同、出生日期±1个月且无百日咳既往病史。
  • 最终纳入病例组与对照组各893例,通过哨点医院信息管理系统和江苏省儿童预防接种信息系统收集人口学及免疫接种信息。
  • 采用条件logistic回归模型分析aPV的VE,VE=(1-OR)×100%。

主要发现

  • 病例组与对照组中男性均占58.12%(519例),两组年龄构成差异无统计学意义(P=0.380)。
  • aPV预防百日咳的总体VE为74.87%(95%CI:60.46%~84.64%)。
  • 接种1、2、3、4剂aPV的VE分别为45.88%(95%CI:-3.72%~72.00%)、73.81%(95%CI:48.64%~86.91%)、78.62%(95%CI:65.52%~87.20%)、74.42%(95%CI:59.49%~84.45%)。
  • 完成4剂次接种且接种后时间间隔1~11、12~23、24~35、36~54月的VE分别为79.89%(95%CI:65.94%~88.48%)、78.39%(95%CI:64.03%~87.43%)、76.23%(95%CI:60.56%~86.13%)和70.61%(95%CI:51.50%~82.75%)。

临床怎么用

  • 监测数据显示aPV对4月龄至6岁儿童百日咳具有较好保护效果,支持按免疫程序完成接种。
  • 末剂接种后VE随时间推移呈衰减趋势,提示需关注完成全程接种后远期保护效果的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the vaccine effectiveness (VE) of acellular pertussis vaccine (aPV) in children aged 4 months to 6 years. Methods: Children aged 4 months to 6 years presenting with cough at sentinel surveillance hospitals in Jiangsu Province in 2024 and undergoing pertussis laboratory testing were enrolled. A case-control study design was employed, with pertussis nucleic acid test-positive cases selected in the case group. A 1∶1 individual matching method was used to select the control group, with matching factors including identical or adjacent residential subdistrict/township, same gender, birth date within ±1 month, and no history of pertussis in the control group. A total of 893 cases and 893 controls were included in the study. Demographic data and immunisation information were collected from the sentinel hospital information management system and the Jiangsu Province Childhood Immunisation Information System. Conditional logistic regression models were used to analyse the VE of aPV, calculated as VE=(1-OR)×100%. Results: Males accounted for 58.12% (519 cases) in both the case group and the control group. There was no statistically significant difference in age distribution between the two groups (P=0.380). The overall VE of aPV against pertussis was 74.87% (95%CI: 60.46%-84.64%). The VE for doses 1, 2, 3, and 4 of aPV was 45.88% (95%CI:-3.72%-72.00%), 73.81% (95%CI: 48.64%-86.91%), 78.62% (95%CI: 65.52%-87.20%), and 74.42% (95%CI: 59.49%-84.45%), respectively. The VE after completing 4 doses of vaccination with time intervals of 1-11, 12-23, 24-35, and 36-54 months was 79.89% (95%CI: 65.94%-88.48%), 78.39% (95%CI: 64.03%-87.43%), 76.23% (95%CI: 60.56%-86.13%), and 70.61%(95%CI:51.50%-82.75%), respectively. Conclusion: aPV has a good overall VE in preventing pertussis in children. After the final dose of vaccination, VE shows a decreasing trend over time. 目的: 评价含无细胞百日咳成分疫苗(aPV)对4月龄至6岁儿童的保护效果(VE)。 方法: 选取2024年在江苏省百日咳哨点监测医院因咳嗽就诊并开展百日咳实验室检测的4月龄至6岁儿童为研究对象,采用病例对照研究设计,将百日咳核酸检测阳性者作为病例组,采用1∶1个体匹配的方法选取对照组,匹配因素包括现住址所在街道或乡镇相同或相邻、性别相同、出生日期为±1个月,且对照组无百日咳既往病史。最终纳入病例组与对照组各893例。通过哨点监测医院信息管理系统和江苏省儿童预防接种信息系统收集研究对象的人口学资料及免疫接种等信息。采用条件logistic回归模型分析aPV的VE,VE=(1-OR)×100%。 结果: 病例组与对照组对象中男性均占58.12%(519例);两组对象的年龄构成差异无统计学意义(P=0.380)。aPV预防百日咳的总体VE为74.87%(95%CI:60.46%~84.64%);接种1、2、3、4剂aPV的VE分别为45.88%(95%CI:-3.72%~72.00%)、73.81%(95%CI:48.64%~86.91%)、78.62%(95%CI:65.52%~87.20%)、74.42%(95%CI:59.49%~84.45%)。完成4剂次接种且接种后时间间隔1~11、12~23、24~35、36~54月的VE分别为79.89%(95%CI:65.94%~88.48%)、78.39%(95%CI:64.03%~87.43%)、76.23%(95%CI:60.56%~86.13%)和70.61%(95%CI:51.50%~82.75%)。 结论: aPV预防儿童百日咳的总体VE较好;末剂接种后VE随时间推移呈衰减趋势。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qi JP, Chen Q, Xu Y, et al. [A matched case-control study on the effectiveness of acellular pertussis-containing vaccine among children aged 4 months to 6 years]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026. PMID: 42128679. doi:10.3760/cma.j.cn112150-20250620-00568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。